This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsFONAR（FOAA）株式概要フォナー・コーポレーションは、その子会社とともに、米国において、人間の病気、異常、その他の病状、傷害を検出・診断するための磁気共鳴画像（MRI）スキャナーの設計、製造、販売に従事している。 詳細FOAA ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績1/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間8%減少しました。 すべてのリスクチェックを見るFOAA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€16.3016.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0123m2016201920222025202620282031Revenue US$123.0mEarnings US$7.4mAdvancedSet Fair ValueView all narrativesFONAR Corporation 競合他社Eckert & ZieglerSymbol: XTRA:EUZMarket cap: €964.3mGeratherm MedicalSymbol: XTRA:GMEMarket cap: €14.5mDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.5bCarl Zeiss MeditecSymbol: XTRA:AFXMarket cap: €2.5b価格と性能株価の高値、安値、推移の概要FONAR過去の株価現在の株価US$16.3052週高値US$16.3052週安値US$11.90ベータ0.961ヶ月の変化1.24%3ヶ月変化3.16%1年変化30.40%3年間の変化1.88%5年間の変化10.14%IPOからの変化42.41%最新ニュースお知らせ • Jun 03+ 3 more updatesFONAR Corporation(NasdaqCM:FONR) dropped from Russell Microcap IndexFONAR Corporation(NasdaqCM:FONR) dropped from Russell Microcap Indexお知らせ • May 06FONAR Corporation, Annual General Meeting, Jun 17, 2026FONAR Corporation, Annual General Meeting, Jun 17, 2026. Location: at the hilton long island huntington hotel, 598 broadholow road, melvile, new york 11747, United Statesお知らせ • Feb 10FONAR Corporation announced delayed 10-Q filingOn 02/09/2026, FONAR Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€81.8m market cap, or US$96.0m).Buy Or Sell Opportunity • Dec 31Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to €15.60. The fair value is estimated to be €12.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.6% over the last 3 years. Earnings per share has declined by 7.2%.お知らせ • Sep 13FONAR Corporation announced delayed annual 10-K filingOn 09/12/2025, FONAR Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Jun 03+ 3 more updatesFONAR Corporation(NasdaqCM:FONR) dropped from Russell Microcap IndexFONAR Corporation(NasdaqCM:FONR) dropped from Russell Microcap Indexお知らせ • May 06FONAR Corporation, Annual General Meeting, Jun 17, 2026FONAR Corporation, Annual General Meeting, Jun 17, 2026. Location: at the hilton long island huntington hotel, 598 broadholow road, melvile, new york 11747, United Statesお知らせ • Feb 10FONAR Corporation announced delayed 10-Q filingOn 02/09/2026, FONAR Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€81.8m market cap, or US$96.0m).Buy Or Sell Opportunity • Dec 31Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to €15.60. The fair value is estimated to be €12.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.6% over the last 3 years. Earnings per share has declined by 7.2%.お知らせ • Sep 13FONAR Corporation announced delayed annual 10-K filingOn 09/12/2025, FONAR Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jul 10Timothy Damadian along with management team and Board of Directors of FONAR Corporation and third parties proposed to acquire remaining 94.99% stake in FONAR Corporation (NasdaqCM:FONR).Timothy Damadian along with management team and Board of Directors of FONAR Corporation and third parties proposed to acquire remaining 94.99% stake in FONAR Corporation (NasdaqCM:FONR) on July 7, 2025. The Proposed Acquisition Group currently beneficially owns approximately 5.01% of the outstanding FONAR Stock. The Board of Directors of FONAR Corporation formed a special committee consisting of independent and disinterested directors of the Board, who will carefully review the proposal to determine the course of action that is in the best interests of FONAR Corporation and all shareholders.お知らせ • Jul 03FONAR Corporation Appoints Robert M. Carrino as an Independent DirectorFONAR Corporation announced that on July 2, 2025, its board of directors appointed Mr. Robert M. Carrino as an independent director of the company’s board of directors. This appointment fills a vacancy on the board left by Ms. Claudette J.V. Chan, who recently retired from her position. Mr. Carrino is a partner at CFGI, LLC in New York City, where he leads the firm’s SPAC practice. He provides complex accounting and consulting services to both public and private companies. Prior to joining CFGI, Mr. Carrino was an audit manager at KPMG, LLP’s Metro New York Long Island Office. Mr. Carrino, a Certified Public Accountant, earned the degree of Bachelor of Science in Business Administration with a concentration in accounting from Western New England University.お知らせ • Jun 25FONAR Corporation Announces Intention of Claudette J.V. Chan to Retire from the Board of Directors and Secretary, Effective June 19, 2025On June 18, 2025, Claudette J.V. Chan, a member of the Board of Directors and the Secretary of FONAR Corporation, notified the Company of her intention to retire from the Company's Board of Directors, and to retire as Secretary of the Company, effective June 19, 2025. Ms. Chan did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.お知らせ • Apr 23FONAR Corporation, Annual General Meeting, May 19, 2025FONAR Corporation, Annual General Meeting, May 19, 2025. Location: hilton long island huntington hotel, 598 broadhollow road, melville, new york 11747, United Statesお知らせ • Feb 15FONAR Corporation announced delayed 10-Q filingOn 02/14/2025, FONAR Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Nov 15First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: US$25.0m (down 3.4% from 1Q 2024). Net income: US$3.14m (down 20% from 1Q 2024). Profit margin: 13% (down from 15% in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year and the company’s share price has also fallen by 1% per year.New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €89.7m (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€89.7m market cap, or US$98.1m).New Risk • Oct 01New major risk - Revenue and earnings growthEarnings have declined by 3.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Sep 29Full year 2024 earnings released: EPS: US$1,637 (vs US$1,425 in FY 2023)Full year 2024 results: EPS: US$1,637 (up from US$1,425 in FY 2023). Revenue: US$102.9b (up 4.3% from FY 2023). Net income: US$10.6b (up 13% from FY 2023). Profit margin: 10% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 28FONAR Corporation to Report Fiscal Year 2024 Results on Sep 27, 2024FONAR Corporation announced that they will report fiscal year 2024 results on Sep 27, 2024Reported Earnings • May 17Third quarter 2024 earnings released: EPS: US$0.28 (vs US$0.55 in 3Q 2023)Third quarter 2024 results: EPS: US$0.28 (down from US$0.55 in 3Q 2023). Revenue: US$25.7m (up 1.2% from 3Q 2023). Net income: US$1.87m (down 49% from 3Q 2023). Profit margin: 7.3% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 1% per year.お知らせ • Apr 09FONAR Corporation, Annual General Meeting, May 20, 2024FONAR Corporation, Annual General Meeting, May 20, 2024, at 10:00 US Eastern Standard Time. Location: The Hilton Long Island Huntington Hotel, 598 Broadhollow Road, Melville New York United States Agenda: To elect five Directors to the Board of Directors; to approve, on an advisory basis, the compensation of the Company’s named executive officers; to recommend, on an advisory basis, whether the advisory stockholder vote to approve the compensation of the Company’s named executive officers be taken every year, every two years, or every three years; to ratify the selection of Marcum LLP as the Company’s auditors for the fiscal year ending June 30, 2024; and to transact such other business as may properly come before the meeting.Reported Earnings • Feb 16Second quarter 2024 earnings released: EPS: US$0.59 (vs US$0.32 in 2Q 2023)Second quarter 2024 results: EPS: US$0.59 (up from US$0.32 in 2Q 2023). Revenue: US$25.4m (up 4.7% from 2Q 2023). Net income: US$3.76m (up 76% from 2Q 2023). Profit margin: 15% (up from 8.8% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 9% per year.Reported Earnings • Nov 16First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: US$25.8m (up 11% from 1Q 2023). Net income: US$4.11m (up 110% from 1Q 2023). Profit margin: 16% (up from 8.4% in 1Q 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €14.90, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 30x in the Medical Equipment industry in Germany. Total loss to shareholders of 9.1% over the past three years.New Risk • Oct 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €95.3m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€95.3m market cap, or US$100.0m).Reported Earnings • Sep 29Full year 2023 earnings released: EPS: US$1.37 (vs US$1.78 in FY 2022)Full year 2023 results: EPS: US$1.37 (down from US$1.78 in FY 2022). Revenue: US$98.6m (up 1.1% from FY 2022). Net income: US$9.38m (down 21% from FY 2022). Profit margin: 9.5% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • May 16Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: US$25.4m (up 3.5% from 3Q 2022). Net income: US$3.69m (up 69% from 3Q 2022). Profit margin: 14% (up from 8.9% in 3Q 2022). The increase in margin was primarily driven by higher revenue.Reported Earnings • Feb 15Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.57 in 2Q 2022)Second quarter 2023 results: EPS: US$0.34 (down from US$0.57 in 2Q 2022). Revenue: US$24.3m (flat on 2Q 2022). Net income: US$2.23m (down 42% from 2Q 2022). Profit margin: 9.2% (down from 16% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year.Reported Earnings • Nov 16First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: US$23.2m (down 2.3% from 1Q 2022). Net income: US$2.05m (down 45% from 1Q 2022). Profit margin: 8.8% (down from 16% in 1Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 3% per year.Recent Insider Transactions • Oct 05Key Executive recently bought €67k worth of stockOn the 30th of September, Luciano Bonanni bought around 5k shares on-market at roughly €14.34 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Luciano's only on-market trade for the last 12 months.お知らせ • Sep 30FONAR Corporation (NasdaqCM:FONR) announces an Equity Buyback for $9 million worth of its shares.FONAR Corporation (NasdaqCM:FONR) announces a share repurchase program. Under the program, the company will repurchase its own shares. The program has no expiration date. On September 26, 2022, the company announced that the Board of Directors has approved up to $9 million to be repurchased under the program.Reported Earnings • Sep 29Full year 2022 earnings released: EPS: US$1.71 (vs US$1.46 in FY 2021)Full year 2022 results: EPS: US$1.71 (up from US$1.46 in FY 2021). Revenue: US$97.6m (up 8.5% from FY 2021). Net income: US$11.9m (up 22% from FY 2021). Profit margin: 12% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 8% per year.お知らせ • Aug 13FONAR Corporation Announces Passing of Its Chairman of the Board of Directors, Raymond V. DamadianFonar Corporation and it’s board of directors reported the passing of its Chairman of the Board of Directors, Raymond V. Damadian, on August 3, 2022. Highlights of the life of Dr. Raymond Damadian: Founded FONAR Corporation (1978), the first company in the MRI industry, maker of the QED80, the world’s first MRI scanner (1980); Conceived the idea for MRI in 1969; Made the discovery in 1970 that is the basis for the making of every MRI image ever produced, the foundation of the MRI industry. Dr. Damadian discovered that there is a marked difference in the relaxation times of NMR (MRI) signals from normal and cancerous tissues of the same type, as well as from different types of normal tissues. This discovery, published in the peer-reviewed journal ‘Science’ in March 1971 marked the beginning of the MRI industry.; Awarded the world’s first MRI patent (filed in March 1971). This patent was upheld in FONAR’s successful lawsuit against General Electric in 1995.; Built the world’s first MRI scanner, Indomitable, which produced the world’s first MRI scan on July 3, 1977.; Awarded The National Medal of Technology by President Ronald Reagan in 1988.; Inducted into the National Inventors Hall of Fame in 1989, joining a select group of renowned pioneers, including Orville and Wilbur Wright, Henry Ford, Thomas Edison and Alexander Graham Bell. Received the Excellence in Medicine award from the Chiari & Syringomyelia Foundation (CSF) in London England on November 10, 2018.Reported Earnings • May 17Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.55 in 3Q 2021)Third quarter 2022 results: EPS: US$0.33 (down from US$0.55 in 3Q 2021). Revenue: US$24.6m (up 6.4% from 3Q 2021). Net income: US$2.19m (down 41% from 3Q 2021). Profit margin: 8.9% (down from 16% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • Apr 09FONAR Corporation, Annual General Meeting, May 23, 2022FONAR Corporation, Annual General Meeting, May 23, 2022. Location: Double Tree Hotel, Wilmington Downtown, 700 King Street, Wilmington, Delaware 19801 (302-655-0400) New York United States Agenda: To elect five Directors to the Board of Directors; To approve, on an advisory basis, the compensation of the Company’s named executive officers; To ratify the selection of Marcum LLP as the Company’s auditors for the fiscal year ending June 30, 2022; To transact such other business as may properly come before the meeting.Buying Opportunity • Mar 12Now 20% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be US$19.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 27% per annum over the last 3 years.Reported Earnings • Feb 15Second quarter 2022 earnings: Revenues in line with analyst expectationsSecond quarter 2022 results: Revenue: US$24.5m (up 16% from 2Q 2021). Net income: US$3.84m (up 29% from 2Q 2021). Profit margin: 16% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Reported Earnings • Sep 29Full year 2021 earnings released: EPS US$1.51 (vs US$1.20 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$89.9m (up 4.9% from FY 2020). Net income: US$10.2m (up 30% from FY 2020). Profit margin: 11% (up from 9.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.お知らせ • Jun 28+ 8 more updatesFONAR Corporation(NasdaqCM:FONR) dropped from Russell 2000 Defensive IndexFONAR Corporation(NasdaqCM:FONR) dropped from Russell 2000 Defensive IndexReported Earnings • May 15Third quarter 2021 earnings released: EPS US$0.53 (vs US$0.18 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$23.1m (up 6.5% from 3Q 2020). Net income: US$3.69m (up 207% from 3Q 2020). Profit margin: 16% (up from 5.6% in 3Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Mar 03New 90-day high: €16.60The company is up 5.0% from its price of €15.80 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.Reported Earnings • Feb 19Second quarter 2021 earnings released: EPS US$0.43 (vs US$0.45 in 2Q 2020)The company reported a soft second quarter result with weaker revenues, although earnings and profit margins were flat. Second quarter 2021 results: Revenue: US$21.2m (down 1.3% from 2Q 2020). Net income: US$2.97m (flat on 2Q 2020). Profit margin: 14% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 29New 90-day low: €14.00The company is down 25% from its price of €18.60 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period.お知らせ • Sep 30FONAR Corporation announced delayed amended 10-K filingOn 09/29/2020, FONAR Corporation announced that they will be unable to file their amended 10-K by the deadline required by the SEC.Reported Earnings • Sep 29Full year earnings released - EPS €1.20Over the last 12 months the company has reported total profits of US$7.86m, down 46% from the prior year. Total revenue was US$85.7m over the last 12 months, down 1.7% from the prior year. Profit margins were 9.2%, which is lower than the 17% margin from last year. The decrease in margin was primarily driven by higher expenses.株主還元FOAADE Medical EquipmentDE 市場7D0%0.7%-0.8%1Y30.4%-27.9%2.2%株主還元を見る業界別リターン: FOAA過去 1 年間で-27.9 % の収益を上げたGerman Medical Equipment業界を上回りました。リターン対市場: FOAA過去 1 年間で2.2 % の収益を上げたGerman市場を上回りました。価格変動Is FOAA's price volatile compared to industry and market?FOAA volatilityFOAA Average Weekly Movement1.4%Medical Equipment Industry Average Movement5.8%Market Average Movement5.7%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.8%安定した株価: FOAA 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: FOAAの 週次ボラティリティ ( 1% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1978535Tim Damadianwww.fonar.comフォナー・コーポレーションは、その子会社とともに、米国で人の病気、異常、その他の病状、傷害を検出・診断するための磁気共鳴画像（MRI）スキャナーの設計、製造、販売に従事している。医療機器事業、医師管理・診断サービス事業の2つの分野で事業を展開。同社はアップライトMRIスキャナーを提供しており、立位、座位、屈伸、横臥などの体重のかかる状態でのスキャンが可能である。また、管理サービス、請求・回収サービス、資格認定サービス、契約交渉、コンプライアンス・コンサルティング、ITサービスの購入、非医療従事者の採用・面接・研修・監督・管理、医療記録の保管、オフィススペース、設備、修理メンテナンスサービス、経理、コンプライアンス問題の支援、診療所の成長とマーケティング戦略の開発・実施を含む非医療管理も提供している。また、画像診断施設の所有・運営も行っている。同社はスキャナーを民間の画像診断センターや病院の外来画像診断施設に販売している。フォナー・コーポレーションは1978年に設立され、ニューヨーク州メルビルに本社を置いている。もっと見るFONAR Corporation 基礎のまとめFONAR の収益と売上を時価総額と比較するとどうか。FOAA 基礎統計学時価総額€107.84m収益（TTM）€5.49m売上高(TTM)€90.82m19.6xPER（株価収益率1.2xP/SレシオFOAA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計FOAA 損益計算書（TTM）収益US$105.34m売上原価US$62.93m売上総利益US$42.41mその他の費用US$36.04m収益US$6.37m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.97グロス・マージン40.26%純利益率6.05%有利子負債／自己資本比率0%FOAA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/04 13:13終値2026/06/02 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋FONAR Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 03+ 3 more updatesFONAR Corporation(NasdaqCM:FONR) dropped from Russell Microcap IndexFONAR Corporation(NasdaqCM:FONR) dropped from Russell Microcap Index
お知らせ • May 06FONAR Corporation, Annual General Meeting, Jun 17, 2026FONAR Corporation, Annual General Meeting, Jun 17, 2026. Location: at the hilton long island huntington hotel, 598 broadholow road, melvile, new york 11747, United States
お知らせ • Feb 10FONAR Corporation announced delayed 10-Q filingOn 02/09/2026, FONAR Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€81.8m market cap, or US$96.0m).
Buy Or Sell Opportunity • Dec 31Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to €15.60. The fair value is estimated to be €12.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.6% over the last 3 years. Earnings per share has declined by 7.2%.
お知らせ • Sep 13FONAR Corporation announced delayed annual 10-K filingOn 09/12/2025, FONAR Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jun 03+ 3 more updatesFONAR Corporation(NasdaqCM:FONR) dropped from Russell Microcap IndexFONAR Corporation(NasdaqCM:FONR) dropped from Russell Microcap Index
お知らせ • May 06FONAR Corporation, Annual General Meeting, Jun 17, 2026FONAR Corporation, Annual General Meeting, Jun 17, 2026. Location: at the hilton long island huntington hotel, 598 broadholow road, melvile, new york 11747, United States
お知らせ • Feb 10FONAR Corporation announced delayed 10-Q filingOn 02/09/2026, FONAR Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€81.8m market cap, or US$96.0m).
Buy Or Sell Opportunity • Dec 31Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to €15.60. The fair value is estimated to be €12.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.6% over the last 3 years. Earnings per share has declined by 7.2%.
お知らせ • Sep 13FONAR Corporation announced delayed annual 10-K filingOn 09/12/2025, FONAR Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jul 10Timothy Damadian along with management team and Board of Directors of FONAR Corporation and third parties proposed to acquire remaining 94.99% stake in FONAR Corporation (NasdaqCM:FONR).Timothy Damadian along with management team and Board of Directors of FONAR Corporation and third parties proposed to acquire remaining 94.99% stake in FONAR Corporation (NasdaqCM:FONR) on July 7, 2025. The Proposed Acquisition Group currently beneficially owns approximately 5.01% of the outstanding FONAR Stock. The Board of Directors of FONAR Corporation formed a special committee consisting of independent and disinterested directors of the Board, who will carefully review the proposal to determine the course of action that is in the best interests of FONAR Corporation and all shareholders.
お知らせ • Jul 03FONAR Corporation Appoints Robert M. Carrino as an Independent DirectorFONAR Corporation announced that on July 2, 2025, its board of directors appointed Mr. Robert M. Carrino as an independent director of the company’s board of directors. This appointment fills a vacancy on the board left by Ms. Claudette J.V. Chan, who recently retired from her position. Mr. Carrino is a partner at CFGI, LLC in New York City, where he leads the firm’s SPAC practice. He provides complex accounting and consulting services to both public and private companies. Prior to joining CFGI, Mr. Carrino was an audit manager at KPMG, LLP’s Metro New York Long Island Office. Mr. Carrino, a Certified Public Accountant, earned the degree of Bachelor of Science in Business Administration with a concentration in accounting from Western New England University.
お知らせ • Jun 25FONAR Corporation Announces Intention of Claudette J.V. Chan to Retire from the Board of Directors and Secretary, Effective June 19, 2025On June 18, 2025, Claudette J.V. Chan, a member of the Board of Directors and the Secretary of FONAR Corporation, notified the Company of her intention to retire from the Company's Board of Directors, and to retire as Secretary of the Company, effective June 19, 2025. Ms. Chan did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.
お知らせ • Apr 23FONAR Corporation, Annual General Meeting, May 19, 2025FONAR Corporation, Annual General Meeting, May 19, 2025. Location: hilton long island huntington hotel, 598 broadhollow road, melville, new york 11747, United States
お知らせ • Feb 15FONAR Corporation announced delayed 10-Q filingOn 02/14/2025, FONAR Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Nov 15First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: US$25.0m (down 3.4% from 1Q 2024). Net income: US$3.14m (down 20% from 1Q 2024). Profit margin: 13% (down from 15% in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year and the company’s share price has also fallen by 1% per year.
New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €89.7m (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€89.7m market cap, or US$98.1m).
New Risk • Oct 01New major risk - Revenue and earnings growthEarnings have declined by 3.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Sep 29Full year 2024 earnings released: EPS: US$1,637 (vs US$1,425 in FY 2023)Full year 2024 results: EPS: US$1,637 (up from US$1,425 in FY 2023). Revenue: US$102.9b (up 4.3% from FY 2023). Net income: US$10.6b (up 13% from FY 2023). Profit margin: 10% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 28FONAR Corporation to Report Fiscal Year 2024 Results on Sep 27, 2024FONAR Corporation announced that they will report fiscal year 2024 results on Sep 27, 2024
Reported Earnings • May 17Third quarter 2024 earnings released: EPS: US$0.28 (vs US$0.55 in 3Q 2023)Third quarter 2024 results: EPS: US$0.28 (down from US$0.55 in 3Q 2023). Revenue: US$25.7m (up 1.2% from 3Q 2023). Net income: US$1.87m (down 49% from 3Q 2023). Profit margin: 7.3% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 1% per year.
お知らせ • Apr 09FONAR Corporation, Annual General Meeting, May 20, 2024FONAR Corporation, Annual General Meeting, May 20, 2024, at 10:00 US Eastern Standard Time. Location: The Hilton Long Island Huntington Hotel, 598 Broadhollow Road, Melville New York United States Agenda: To elect five Directors to the Board of Directors; to approve, on an advisory basis, the compensation of the Company’s named executive officers; to recommend, on an advisory basis, whether the advisory stockholder vote to approve the compensation of the Company’s named executive officers be taken every year, every two years, or every three years; to ratify the selection of Marcum LLP as the Company’s auditors for the fiscal year ending June 30, 2024; and to transact such other business as may properly come before the meeting.
Reported Earnings • Feb 16Second quarter 2024 earnings released: EPS: US$0.59 (vs US$0.32 in 2Q 2023)Second quarter 2024 results: EPS: US$0.59 (up from US$0.32 in 2Q 2023). Revenue: US$25.4m (up 4.7% from 2Q 2023). Net income: US$3.76m (up 76% from 2Q 2023). Profit margin: 15% (up from 8.8% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 9% per year.
Reported Earnings • Nov 16First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: US$25.8m (up 11% from 1Q 2023). Net income: US$4.11m (up 110% from 1Q 2023). Profit margin: 16% (up from 8.4% in 1Q 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €14.90, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 30x in the Medical Equipment industry in Germany. Total loss to shareholders of 9.1% over the past three years.
New Risk • Oct 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €95.3m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€95.3m market cap, or US$100.0m).
Reported Earnings • Sep 29Full year 2023 earnings released: EPS: US$1.37 (vs US$1.78 in FY 2022)Full year 2023 results: EPS: US$1.37 (down from US$1.78 in FY 2022). Revenue: US$98.6m (up 1.1% from FY 2022). Net income: US$9.38m (down 21% from FY 2022). Profit margin: 9.5% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • May 16Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: US$25.4m (up 3.5% from 3Q 2022). Net income: US$3.69m (up 69% from 3Q 2022). Profit margin: 14% (up from 8.9% in 3Q 2022). The increase in margin was primarily driven by higher revenue.
Reported Earnings • Feb 15Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.57 in 2Q 2022)Second quarter 2023 results: EPS: US$0.34 (down from US$0.57 in 2Q 2022). Revenue: US$24.3m (flat on 2Q 2022). Net income: US$2.23m (down 42% from 2Q 2022). Profit margin: 9.2% (down from 16% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year.
Reported Earnings • Nov 16First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: US$23.2m (down 2.3% from 1Q 2022). Net income: US$2.05m (down 45% from 1Q 2022). Profit margin: 8.8% (down from 16% in 1Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 3% per year.
Recent Insider Transactions • Oct 05Key Executive recently bought €67k worth of stockOn the 30th of September, Luciano Bonanni bought around 5k shares on-market at roughly €14.34 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Luciano's only on-market trade for the last 12 months.
お知らせ • Sep 30FONAR Corporation (NasdaqCM:FONR) announces an Equity Buyback for $9 million worth of its shares.FONAR Corporation (NasdaqCM:FONR) announces a share repurchase program. Under the program, the company will repurchase its own shares. The program has no expiration date. On September 26, 2022, the company announced that the Board of Directors has approved up to $9 million to be repurchased under the program.
Reported Earnings • Sep 29Full year 2022 earnings released: EPS: US$1.71 (vs US$1.46 in FY 2021)Full year 2022 results: EPS: US$1.71 (up from US$1.46 in FY 2021). Revenue: US$97.6m (up 8.5% from FY 2021). Net income: US$11.9m (up 22% from FY 2021). Profit margin: 12% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 8% per year.
お知らせ • Aug 13FONAR Corporation Announces Passing of Its Chairman of the Board of Directors, Raymond V. DamadianFonar Corporation and it’s board of directors reported the passing of its Chairman of the Board of Directors, Raymond V. Damadian, on August 3, 2022. Highlights of the life of Dr. Raymond Damadian: Founded FONAR Corporation (1978), the first company in the MRI industry, maker of the QED80, the world’s first MRI scanner (1980); Conceived the idea for MRI in 1969; Made the discovery in 1970 that is the basis for the making of every MRI image ever produced, the foundation of the MRI industry. Dr. Damadian discovered that there is a marked difference in the relaxation times of NMR (MRI) signals from normal and cancerous tissues of the same type, as well as from different types of normal tissues. This discovery, published in the peer-reviewed journal ‘Science’ in March 1971 marked the beginning of the MRI industry.; Awarded the world’s first MRI patent (filed in March 1971). This patent was upheld in FONAR’s successful lawsuit against General Electric in 1995.; Built the world’s first MRI scanner, Indomitable, which produced the world’s first MRI scan on July 3, 1977.; Awarded The National Medal of Technology by President Ronald Reagan in 1988.; Inducted into the National Inventors Hall of Fame in 1989, joining a select group of renowned pioneers, including Orville and Wilbur Wright, Henry Ford, Thomas Edison and Alexander Graham Bell. Received the Excellence in Medicine award from the Chiari & Syringomyelia Foundation (CSF) in London England on November 10, 2018.
Reported Earnings • May 17Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.55 in 3Q 2021)Third quarter 2022 results: EPS: US$0.33 (down from US$0.55 in 3Q 2021). Revenue: US$24.6m (up 6.4% from 3Q 2021). Net income: US$2.19m (down 41% from 3Q 2021). Profit margin: 8.9% (down from 16% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 09FONAR Corporation, Annual General Meeting, May 23, 2022FONAR Corporation, Annual General Meeting, May 23, 2022. Location: Double Tree Hotel, Wilmington Downtown, 700 King Street, Wilmington, Delaware 19801 (302-655-0400) New York United States Agenda: To elect five Directors to the Board of Directors; To approve, on an advisory basis, the compensation of the Company’s named executive officers; To ratify the selection of Marcum LLP as the Company’s auditors for the fiscal year ending June 30, 2022; To transact such other business as may properly come before the meeting.
Buying Opportunity • Mar 12Now 20% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be US$19.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 27% per annum over the last 3 years.
Reported Earnings • Feb 15Second quarter 2022 earnings: Revenues in line with analyst expectationsSecond quarter 2022 results: Revenue: US$24.5m (up 16% from 2Q 2021). Net income: US$3.84m (up 29% from 2Q 2021). Profit margin: 16% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Reported Earnings • Sep 29Full year 2021 earnings released: EPS US$1.51 (vs US$1.20 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$89.9m (up 4.9% from FY 2020). Net income: US$10.2m (up 30% from FY 2020). Profit margin: 11% (up from 9.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 28+ 8 more updatesFONAR Corporation(NasdaqCM:FONR) dropped from Russell 2000 Defensive IndexFONAR Corporation(NasdaqCM:FONR) dropped from Russell 2000 Defensive Index
Reported Earnings • May 15Third quarter 2021 earnings released: EPS US$0.53 (vs US$0.18 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$23.1m (up 6.5% from 3Q 2020). Net income: US$3.69m (up 207% from 3Q 2020). Profit margin: 16% (up from 5.6% in 3Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Mar 03New 90-day high: €16.60The company is up 5.0% from its price of €15.80 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.
Reported Earnings • Feb 19Second quarter 2021 earnings released: EPS US$0.43 (vs US$0.45 in 2Q 2020)The company reported a soft second quarter result with weaker revenues, although earnings and profit margins were flat. Second quarter 2021 results: Revenue: US$21.2m (down 1.3% from 2Q 2020). Net income: US$2.97m (flat on 2Q 2020). Profit margin: 14% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 29New 90-day low: €14.00The company is down 25% from its price of €18.60 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period.
お知らせ • Sep 30FONAR Corporation announced delayed amended 10-K filingOn 09/29/2020, FONAR Corporation announced that they will be unable to file their amended 10-K by the deadline required by the SEC.
Reported Earnings • Sep 29Full year earnings released - EPS €1.20Over the last 12 months the company has reported total profits of US$7.86m, down 46% from the prior year. Total revenue was US$85.7m over the last 12 months, down 1.7% from the prior year. Profit margins were 9.2%, which is lower than the 17% margin from last year. The decrease in margin was primarily driven by higher expenses.
